These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 1484260)
21. Reduction in vulnerability to ventricular fibrillation by bromocriptine, a dopamine agonist. Falk RH; Desilva RD; Lown B Cardiovasc Res; 1981 Mar; 15(3):175-80. PubMed ID: 7260985 [TBL] [Abstract][Full Text] [Related]
22. Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Sharif NA; McLaughlin MA; Kelly CR; Katoli P; Drace C; Husain S; Crosson C; Toris C; Zhan GL; Camras C Exp Eye Res; 2009 Mar; 88(3):386-97. PubMed ID: 18992242 [TBL] [Abstract][Full Text] [Related]
23. Dopamine, dopaminergic drugs and ocular hypertension. Virno M; Gazzaniga A; Taverniti L; Pecori Giraldi J; De Gregorio F Int Ophthalmol; 1992 Sep; 16(4-5):349-53. PubMed ID: 1358853 [TBL] [Abstract][Full Text] [Related]
24. Structural requirements of flavonoids for increment of ocular blood flow in the rabbit and retinal function recovery in rat eyes. Park YH; Xu XR; Chiou GC J Ocul Pharmacol Ther; 2004 Jun; 20(3):189-200. PubMed ID: 15279724 [TBL] [Abstract][Full Text] [Related]
25. Neuronal and postjunctional components in the blood pressure effects of dopamine and bromocriptine in rabbits. Ensinger H; Majewski H; Hedler L; Starke K J Pharmacol Exp Ther; 1985 Sep; 234(3):681-90. PubMed ID: 2993590 [TBL] [Abstract][Full Text] [Related]
26. Effects of dopamine and bromocriptine on colonic motility in dog. Bueno L; Fargeas MJ; Fioramonti J; Honde C Br J Pharmacol; 1984 May; 82(1):35-42. PubMed ID: 6145468 [TBL] [Abstract][Full Text] [Related]
27. Role of Histamine H₃ Receptor Antagonists on Intraocular Pressure Reduction in Rabbit Models of Transient Ocular Hypertension and Glaucoma. Lanzi C; Lucarini L; Durante M; Sgambellone S; Pini A; Catarinicchia S; Łażewska D; Kieć-Kononowicz K; Stark H; Masini E Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30813468 [TBL] [Abstract][Full Text] [Related]
28. Effects of dopamine antagonists on retinal B-wave recovery after retinal ischemia. Chiou GC; Li BH J Ocul Pharmacol; 1993; 9(2):179-85. PubMed ID: 8345291 [TBL] [Abstract][Full Text] [Related]
29. Vaninolol: a novel compound for the treatment of glaucoma and ischemic retinopathy. Wu BN; Hong SJ; Sheu MM; Chen IJ; Liu SX; Chiou GC J Ocul Pharmacol Ther; 1995; 11(3):213-20. PubMed ID: 8590252 [TBL] [Abstract][Full Text] [Related]
30. Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent. Chu TC; He Q; Potter DE J Ocul Pharmacol Ther; 2002 Dec; 18(6):507-14. PubMed ID: 12537677 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of haloperidol, a dopamine antagonist, on intraocular pressure in experimental glaucoma. Khosla P; Kothari S; Gupta MC; Srivastava RK Indian J Exp Biol; 1996 Jun; 34(6):580-1. PubMed ID: 8792645 [TBL] [Abstract][Full Text] [Related]
32. Treatment of ocular hypertension and glaucoma with dopamine antagonists. Chiou GC Ophthalmic Res; 1984; 16(3):129-34. PubMed ID: 6147806 [TBL] [Abstract][Full Text] [Related]
33. A comparison of the ocular hypotensive effect of 0.025% bromocriptine and 0.25% timolol eye drops in normal human volunteers. al-Sereiti MR; Coakes RL; O'Sullivan DP; Turner P Br J Clin Pharmacol; 1989 Oct; 28(4):443-7. PubMed ID: 2590602 [TBL] [Abstract][Full Text] [Related]
34. Short-term effect of latanoprost on ocular circulation in ocular hypertension. Akarsu C; Bilgili YK; Taner P; Unal B; Ergin A Clin Exp Ophthalmol; 2004 Aug; 32(4):373-7. PubMed ID: 15281970 [TBL] [Abstract][Full Text] [Related]
35. Ocular effects of a relatively selective alpha 2 agonist (UK-14, 304-18) in cats, rabbits and monkeys. Burke JA; Potter DE Curr Eye Res; 1986 Sep; 5(9):665-76. PubMed ID: 2876846 [TBL] [Abstract][Full Text] [Related]
36. LY141865: a relatively selective DA2 agonist with complex ocular activity. Potter DE; Burke JA J Ocul Pharmacol; 1988; 4(1):19-28. PubMed ID: 2902177 [TBL] [Abstract][Full Text] [Related]
37. Mechanisms and sites of ocular action of 7-hydroxy-2-dipropylaminotetralin: a dopamine(3) receptor agonist. Chu E; Chu TC; Potter DE J Pharmacol Exp Ther; 2000 Jun; 293(3):710-6. PubMed ID: 10869368 [TBL] [Abstract][Full Text] [Related]
38. Ocular hypotensive and vasodilative effects of two beta-adrenergic blockers with intrinsic sympathomimetic activity. Hong SJ; Wu KY; Chen IJ Curr Eye Res; 1998 Jul; 17(7):700-7. PubMed ID: 9678415 [TBL] [Abstract][Full Text] [Related]
39. The extracerebral dopamine antagonist domperidone block the suppressive effect of bromocriptine on prolactin and TSH secretion in man. Svet-Moldavsky I; Svet-Moldavsky G; Zinzar S; Holland J; Vergara C; Arlin Z; Koziner B; Clarkson B Biomedicine; 1981 Oct; 35(5):142-4. PubMed ID: 6797487 [TBL] [Abstract][Full Text] [Related]
40. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. Sharif NA Curr Drug Targets; 2010 Aug; 11(8):978-93. PubMed ID: 20426763 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]